The Paradigm Evolves
November 13 – 14, 2019 • Harvard Medical School, Boston, MA
The 15th Annual Personalized Medicine Conference at Harvard Medical School will explore the science, business, and policy issues facing personalized medicine as scientists refine their understanding of how groundbreaking molecular diagnostics augmented by artificial intelligence, advanced data analytics, and digital health applications can empower both physicians and patients with information about how an expanded set of biological characteristics — including those found in the proteome and microbiome — may influence their health and their responses to increasingly impactful therapies.
[As] physiologic data points are integrated with other parameters such as genomics and metabolomics … [personalized medicine] may move from a reactive state to a proactive state.”— William S. Dalton, Ph.D., M.D., Founder, Executive Chairman, M2Gen
With new biomarkers coming on line, we probably will be able to diagnose much better who will respond best to therapy. That means we have to develop drugs and diagnostics together.”— Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson
Momentum toward a universal digital future in health care is advancing. Due to the great promise of these technologies ... FDA is working to modernize our regulatory approach to better enable and more efficiently spur innovation.”— Jeffrey E. Shuren, M.D., J.D., Director, Center for Devices and Radiological Health, U.S. Food and Drug Administration
Bonnie J. Addario
GO2 Foundation for Lung Cancer
Sarah K. Emond, M.P.P.
Executive Vice President, Chief Operating Officer
Institute for Clinical and Economic Review
Kris Joshi, Ph.D.
Executive Vice President; President, Network Solutions
Peter Maag, Ph.D.
Lincoln Nadauld, M.D., Ph.D.
Chief, Precision Health
Kenna R. Mills Shaw, Ph.D.
MD Anderson Institute for Personalized Cancer Therapy
Michael Sherman, M.D., M.B.A., M.S.
Chief Medical Officer, Senior Vice President
Harvard Pilgrim Health Care
Roy Smythe, M.D.
Paul Stoffels, M.D.
Vice Chairman, Executive Committee; Chief Scientific Officer
Johnson & Johnson